Literature DB >> 17722953

Ampicillin/sulbactam: current status in severe bacterial infections.

Petros I Rafailidis1, Eleni N Ioannidou, Matthew E Falagas.   

Abstract

Ampicillin/sulbactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria. Data from comparative studies justify the use of ampicillin/sulbactam in a 2 : 1 ratio in various severe bacterial infections. In comparative clinical trials, ampicillin/sulbactam has proved to be a significant drug in the therapeutic armamentarium for lower respiratory tract infections and aspiration pneumonia, gynaecological/obstetrical infections, intra-abdominal infections, paediatric infections such as acute epiglottitis and periorbital cellulitis, diabetic foot infections, and skin and soft tissue infections. Of particular interest during this era of increasing antimicrobial resistance in various settings and populations is the effectiveness of sulbactam against a considerable proportion of infections due to Acinetobacter baumannii.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722953     DOI: 10.2165/00003495-200767130-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  102 in total

1.  Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression.

Authors:  K Asada; Y Inaba; E Tateda-Suzuki; K Kuwahara-Arai; T Ito; K Hiramatsu
Journal:  Acta Biochim Pol       Date:  1995       Impact factor: 2.149

2.  Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.

Authors:  C R Messick; M Mamdani; I R McNicholl; L H Danziger; K A Rodvold; R E Condon; A P Walker; C E Edmiston
Journal:  Pharmacotherapy       Date:  1998 Jan-Feb       Impact factor: 4.705

3.  Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data.

Authors:  Krista Lõivukene; Epp Sepp; Vivika Adamson; Piret Mitt; Ulle Kallandi; Karin Otter; Paul Naaber
Journal:  Scand J Infect Dis       Date:  2006

4.  Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.

Authors:  J M Cisneros; M J Reyes; J Pachón; B Becerril; F J Caballero; J L García-Garmendía; C Ortiz; A R Cobacho
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

5.  Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.

Authors:  D A Talan; P H Summanen; S M Finegold
Journal:  Clin Infect Dis       Date:  2000-09-14       Impact factor: 9.079

Review 6.  Experience with ampicillin/sulbactam in severe infections.

Authors:  G Kanra
Journal:  J Int Med Res       Date:  2002       Impact factor: 1.671

7.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.

Authors:  L Löffler; A Bauernfeind; W Keyl
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.

Authors:  Alex P Betrosian; Frantzeska Frantzeskaki; Anna Xanthaki; George Georgiadis
Journal:  Scand J Infect Dis       Date:  2007

10.  Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.

Authors:  Anna S Levin; Carlos E Levy; A Edison I Manrique; Eduardo A S Medeiros; Silvia F Costa
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

View more
  25 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

2.  Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

Authors:  Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

3.  Structural Insights into Inhibition of Escherichia coli Penicillin-binding Protein 1B.

Authors:  Dustin T King; Gregory A Wasney; Michael Nosella; Anita Fong; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2016-11-29       Impact factor: 5.157

4.  Scope and Limitations of Reductive Amination Catalyzed by Half-Sandwich Iridium Complexes Under Mild Reaction Conditions.

Authors:  Dat P Nguyen; Rudolph N Sladek; Loi H Do
Journal:  Tetrahedron Lett       Date:  2020-07-03       Impact factor: 2.415

5.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

6.  An Evaluation of Selected Indications and Appropriateness of Ampicillin/Sulbactam, an Unrestricted Antimicrobial, at a Single Center.

Authors:  Dorothy McCoy; Rani Sebti; Arpi G Kuyumjian
Journal:  P T       Date:  2017-03

Review 7.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 8.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790

Review 9.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

10.  Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules.

Authors:  Noor Akbar; Zara Aslam; Ruqaiyyah Siddiqui; Muhammad Raza Shah; Naveed Ahmed Khan
Journal:  AMB Express       Date:  2021-07-10       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.